PMID- 9249563
OWN - NLM
STAT- MEDLINE
DCOM- 19970903
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 273
IP  - 1 Pt 2
DP  - 1997 Jul
TI  - Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 
      and ANG II.
PG  - R293-300
AB  - In the rat isolated perfused kidney, 5,8,11,14-eicosatetraynoic acid, an 
      inhibitor of all pathways of arachidonic acid (AA) metabolism, diminished 
      endothelin-1 (ET-1)- and angiotensin II (ANG II)-induced renal vasoconstriction 
      by approximately 60-70%. We then examined the individual contribution of each 
      oxygenase, cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P-450 (CYP) 
      to the vasoconstrictor effects of ET-1 and ANG II. Inhibition of COX with 
      indomethacin reduced by 30-40% the vasoconstrictor responses to ET-1 and ANG II. 
      Inhibition of 12-LOX with baicalein and 5- and 12-LOX with 5,8,11-eicosatriynoic 
      acid attenuated ANG II-induced renal vasoconstriction by approximately 40-60% but 
      did not affect responses to ET-1. In contrast, 12,12-dibromododec-11-enoic acid 
      (DBDD), an inhibitor of the CYP omega/omega 1-hydroxylase pathway, diminished 
      ET-1-induced renal vasoconstriction by 30-40%, an effect reproduced by depletion 
      of CYP enzymes with CoCl2. Neither DBDD nor CoCl2 affected renal vasoconstriction 
      elicited by ANG II. ET-1 increased efflux of 19- and 20-hydroxyeicosatetraenoic 
      acid, an effect reduced by DBDD. Thus products of the COX and CYP pathways 
      contribute to the renal vasoconstrictor response to ET-1, whereas COX- and 
      LOX-derived eicosanoids contribute to the response to ANG II, accounting for > or 
      = 80% of the vasoactivity of the peptides.
FAU - Oyekan, A
AU  - Oyekan A
AD  - Department of Pharmacology, New York Medical College, Valhalla 10595, USA.
FAU - Balazy, M
AU  - Balazy M
FAU - McGiff, J C
AU  - McGiff JC
LA  - eng
GR  - R01-25394/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Arachidonic Acids)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Endothelin-1)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Flavanones)
RN  - 0 (Flavonoids)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 11128-99-7 (Angiotensin II)
RN  - 1191-85-1 (5,8,11,14-Eicosatetraynoic Acid)
RN  - 3G0H8C9362 (Cobalt)
RN  - 49QAH60606 (baicalein)
RN  - 9035-51-2 (Cytochrome P-450 Enzyme System)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EVS87XF13W (cobaltous chloride)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - 5,8,11,14-Eicosatetraynoic Acid/pharmacology
MH  - Angiotensin II/*pharmacology
MH  - Animals
MH  - Arachidonic Acids/metabolism/*pharmacology
MH  - Cobalt/pharmacology
MH  - Cyclooxygenase Inhibitors/pharmacology
MH  - Cytochrome P-450 Enzyme System/*metabolism
MH  - Endothelin-1/*pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - *Flavanones
MH  - Flavonoids/pharmacology
MH  - Indomethacin/pharmacology
MH  - Lipoxygenase/*metabolism
MH  - Lipoxygenase Inhibitors/pharmacology
MH  - Male
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Renal Circulation/drug effects/*physiology
MH  - Vasoconstriction/drug effects/*physiology
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - 10.1152/ajpregu.1997.273.1.R293 [doi]
PST - ppublish
SO  - Am J Physiol. 1997 Jul;273(1 Pt 2):R293-300. doi: 
      10.1152/ajpregu.1997.273.1.R293.